← All trials
NCT04602468
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2020
- Primary completion
- Dec 1, 2023
- Completion date
- Jul 1, 2024
- First posted
- Oct 26, 2020
- Last posted
- Jul 1, 2021
- Enrollment
- 237
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Royal College of Surgeons, IrelandLead sponsor
- Erasmus University RotterdamCollaborator
- University of TorontoCollaborator
- National University of IrelandCollaborator
- University of LimerickCollaborator
- Queen's University, BelfastCollaborator
- Cystic Fibrosis Registry of IrelandCollaborator
- Imperial College LondonCollaborator
- TeagascCollaborator
- Medizinische Hochschule Brandenburg Theodor FontaneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.